Online inquiry

IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1381MR)

This product GTTS-WQ1381MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1A&IL1B gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5; NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552; 3553
UniProt ID P01583; P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1381MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15685MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ1444MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ12570MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ9149MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ6043MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ8082MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ14440MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ12767MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-52M51
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW